Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.

Christoph Grundner1, Tajib Mirzabekov, Joseph Sodroski

  • 1Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Boston, Massachusetts 02115, USA.

Journal of Virology
|March 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PE/PPE proteins contribute to Mycobacterium tuberculosis drug resistance.

Nature communications·2026
Same author

Evaluation of Data-Independent Acquisition-Based Phosphoproteomics Analysis in Mammalian and Bacterial Systems.

Journal of proteome research·2026
Same author

The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCC.

Nature communications·2025
Same author

PE/PPE proteins contribute to <i>Mycobacterium tuberculosis</i> drug resistance.

bioRxiv : the preprint server for biology·2025
Same author

Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response.

Nature communications·2025
Same author

Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques.

Journal of virology·2025

Developing effective HIV-1 vaccines is challenging. New proteoliposomes displaying native, trimeric HIV-1 envelope glycoproteins show promise for eliciting broadly neutralizing antibodies, a critical component for an HIV vaccine.

Area of Science:

  • Immunology
  • Virology
  • Biochemistry

Background:

  • The human immunodeficiency virus type 1 (HIV-1) exterior envelope glycoprotein gp120 is key for receptor binding and a target for neutralizing antibodies.
  • Current HIV-1 vaccine strategies struggle to elicit broadly neutralizing antibodies due to immune escape mechanisms and challenges in presenting native viral glycoproteins.

Purpose of the Study:

  • To develop a novel immunogen for HIV vaccine design that presents native, trimeric envelope glycoproteins in a stable format.
  • To overcome limitations of monomeric gp120 and labile trimeric envelope glycoproteins as immunogens.

Main Methods:

  • Solid-phase HIV-1 gp160DeltaCT (cytoplasmic tail-deleted) proteoliposomes (PLs) were created to contain native, trimeric envelope glycoproteins.
  • The conformation and ligand-binding properties of the envelope glycoproteins on PLs were analyzed.

Related Experiment Videos

Main Results:

  • The gp160DeltaCT glycoproteins on proteoliposomes were confirmed to be trimers.
  • These trimeric glycoproteins were recognized by relevant conformational ligands, similar to cell-surface expressed oligomers.

Conclusions:

  • Solid-phase proteoliposomes represent a significant advancement over existing HIV envelope glycoprotein formulations for vaccine development.
  • This novel immunogen platform shows potential for eliciting broadly neutralizing antibodies against HIV-1.